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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Polish language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 154 JIA patients (10.4% systemic, 50.0% oligoarticular, 24.7% RF-negative polyarthritis, 
14.9% other categories) and 91 healthy children, were enrolled in two centres. The JAMAR components discriminated well 
healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the 
Polish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Polish parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
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(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Polish language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] enrolled from March 2012 to 
September 2013. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. assessment of physical function (PF) using 15 items in 
which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 21-num-
bered circle Visual Analogue Scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in two versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
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the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
item–scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be 
lower than their reliability coefficients, as measured by 
Cronbach’s alpha); test–retest reliability or intra-class 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR subscales with 
the 6 JIA core set variables, with the addition of the par-
ent assessment of disease activity and pain by the Spear-
man’s correlation coefficients (r) [17] and the discriminant 
validity, which assesses whether the JAMAR discriminates 
between the different JIA categories and healthy children 
[18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Polish parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Polish JAMAR was fully cross-culturally adapted 
from the standard English version with 3 forward and 2 
backward translations with a concordance for 118/123 
translations lines (96%) for the parent version and 116/120 
lines (97%) for the child version.
The 123 lines were understood by 10/10 of the parents 
(median = 100%; range: 100–100%). The 120 lines of the 
child version were understood by 10/10 (median = 100%; 
range: 100–100%). The text of the parent JAMAR was 
unmodified after the probe technique.
The text of the parent JAMAR was unmodified after the 
probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 156 JIA patients and 92 healthy children (total of 
248 subjects), were enrolled at two paediatric rheumatology 
centres. Two JIA patients and one healthy child did not give 
the consent to use their data.
In the 154 JIA subjects, the JIA categories were 10.4% 
with systemic arthritis, 50.0% with oligoarthritis, 24.7% 
with RF-negative polyarthritis, 5.8% with RF-positive pol-
yarthritis, 5.2% with enthesitis-related arthritis and 3.9% 
with undifferentiated arthritis. Notably, none of the enrolled 
JIA patients is affected with psoriatic arthritis (Table 1).
A total of 243/245 (99.2%) subjects had the parent ver-
sion of the JAMAR completed by a parent (153 from parents 
of JIA patients and 90 from parents of healthy children). The 
JAMAR was completed by 210/243 (86.4%) mothers and 
33/243 (13.6%) fathers. The child version of the JAMAR 
was completed by 208/245 (84.9%) children aged 5.8 or 
older. Also patients younger than 7 years, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing "Results" section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all the JAMAR items the median number of missing 
responses was 2.0 (0.7–2.6).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for item 8, whereas a reduced number 
of response choices was used for PF items 2, 6, 8, 9, 11, 12, 
13, 14 and 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked 
as not applicable was 3% (2–3%) for the PF and 6.5% 
(5–10%) for the HRQoL.
S318 Rheumatology International (2018) 38 (Suppl 1):S315–S321
1 3
Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 154 JIA patients
Data related to the JAMAR refers to the 153 JIA patients and to the 90 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS Visual Analogue 
Scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF− Poly-
arthritis
RF+ Poly-
arthritis
Enthesitis-
related arthritis
Undifferenti-
ated arthritis
All JIA patients Healthy
N = 16 N = 77 N = 38 N = 9 N = 8 N = 6 N = 154 N = 91
Female 8 (50%) 59 (76.6%) 29 (76.3%) 9 (100%) 3 (37.5%) 5 (83.3%) 113 (73.4%) 45 (49.5%)**
Age at visit 11.3 (9.3–14.2) 11.8 (9–14) 13.3 (9.8–15.5) 15.7 (15.4–
16.1)
13.7 (11.6–
16.1)
15.9 (9.3–17) 12.4 (9.5–
15.4)*
10.7 (9.1–14)*
Age at onset 5.1 (2.6–8.5) 6.8 (4.1–9.3) 7.2 (4.6–10.1) 12.9 (11-13.9) 11.9 (8.6–14.5) 11.2 (6.4–11.3) 7 (4.5–10.8)**
Disease duration 6 (1.6–7.7) 3.4 (1.3–6.9) 4.1 (1.8–7.7) 2.9 (1.3–3.8) 1.6 (1–1.9) 3.9 (3.4–4.5) 3.5 (1.4–6.7)
ESR 9 (3–11) 8 (5–13) 10 (6–17) 16 (8–37) 10 (8–12.5) 17.5 (6–67) 9 (6–15)
MD VAS 0 (0–2) 3 (1–5) 4 (1–6) 7 (1–9) 4 (4–4) 2.5 (0–5) 3 (1–5)*
No. swollen joints 0 (0–1) 1 (0–2) 2 (0–4) 2 (0–7) 1.5 (1–3) 1 (0–2) 1 (0–2)*
No. joints with 
pain
0 (0–1) 0 (0–1) 0 (0–4) 2 (0–8) 1 (0.5-2) 0.5 (0–2) 0 (0–2)
No. joints with 
LOM
0 (0–2) 1 (0–2) 2.5 (1–9) 4 (0–8) 1 (0.5–1.5) 0 (0–2) 1 (0–2)*
No. active joints 0 (0–1) 1 (0–2) 2 (0–6) 2 (0–8) 1.5 (1–3) 1 (0–2) 1 (0–2)*
Active systemic 
features
1 (6.3%) 0 (0%) 0 (0%) 1 (11.1%) 0 (0%) 0 (0%) 2/148 (1.4%)
ANA status 2 (12.5%) 25 (32.5%) 9 (23.7%) 4 (44.4%) 0 (0%) 1 (16.7%) 41 (26.6%)
Uveitis 0 (0%) 12 (15.6%) 2/36 (5.6%) 0 (0%) 1 (12.5%) 0 (0%) 15/152 (9.9%)
PF Total Score 0 (0–2) 1 (0–4) 3 (1–8) 3 (2–7) 2.5 (1.5–6.5) 0 (0–4) 2 (0–5)* 0 (0–0)#
Pain VAS 0.5 (0–3) 1 (0–4) 3 (0.5–5) 1 (0.5–5) 2.5 (1–4.3) 1.5 (0–2) 1.3 (0–4.3) 0 (0–0)#
Disease Activity 
VAS
1 (0–3) 2.5 (0.5–5) 3.5 (0.5–6.3) 1.5 (1–6.5) 3 (1.5–5) 4.8 (1-8.3) 2.5 (0.5–6)
Well-being VAS 2 (0–5) 1.5 (0–4) 3.5 (1–5.5) 1 (0.3–6.5) 3 (1–4.3) 1 (1–4) 2 (0.5–5)
HRQoL-PhH 2 (0.5-6) 2 (1–5) 4 (1–7) 4.5 (2.5–7) 3 (2–7) 2 (0–4) 3 (1–6) 0 (0–0)#
HRQoL-PsH 4.5 (1-54.5) 3 (1–5) 4 (3–4) 2.5 (0.5–5) 3.5 (2.5–5) 1 (0–2) 3 (1–5) 0 (0–3)#
HRQoL total 
Score
7.5 (3–58) 6 (2–10) 7 (5–13) 8.5 (3–11) 7.5 (4–10.5) 3 (0–6) 7 (3–10) 0 (0–3)#
Pain/swell. in > 1 
joint
5 (31.3%) 52 (67.5%) 28 (73.7%) 6 (66.7%) 7 (87.5%) 3/5 (60%) 101/153 (66%) 5/90 (5.6%)#
Morning stiff-
ness > 15 min
2 (12.5%) 12/75 (16%) 10 (26.3%) 3 (33.3%) 3 (37.5%) 1/5 (20%) 31/151 (20.5%) 1/90 (1.1%)#
Subjective remis-
sion
4/14 (28.6%) 48/75 (64%) 27 (71.1%) 7 (77.8%) 7 (87.5%) 3/5 (60%) 96/149 
(64.4%)*
In treatment 15 (93.8%) 73 (94.8%) 37 (97.4%) 9 (100%) 8 (100%) 5/5 (100%) 147/153 
(96.1%)
Reporting side 
effects
6/15 (40%) 23/70 (32.9%) 9/35 (25.7%) 3 (33.3%) 8 (100%) 0 (0%) 49/142 (34.5%)
Taking medica-
tion regularly
15/15 (100%) 66/71 (93%) 35/36 (97.2%) 8 (88.9%) 6 (75%) 5/5 (100%) 135/144 
(93.8%)
With problems 
attending school
1/6 (16.7%) 11/38 (28.9%) 8/21 (38.1%) 3/6 (50%) 1/7 (14.3%) 0 (0%) 24/82 (29.3%) 1 (1.1%)#
Satisfied with dis-
ease outcome
15 (93.8%) 62 (80.5%) 28/36 (77.8%) 7 (77.8%) 5 (62.5%) 5/5 (100%) 122/151 
(80.8%)
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Floor and ceiling effect
The median floor effect was 81.0% (69.9–88.9%) for the 
PF items, 47.7% (34.6–54.9%) for the HRQoL-PhH items, 
and 40.5% (37.3–44.4%) for the HRQoL-PsH items. The 
median ceiling effect was 0% (0–1.3%) for the PF items, 
3.3% (3.3–7.8%) for the HRQoL-PhH items, and 2.0% 
(1.3–2.0%) for the HRQoL-PsH items. The median floor 
effect was 28.8% for the pain VAS, 20.3% for the disease 
activity VAS and 22.2% for the well-being VAS. The median 
ceiling effect was 0.6% for the pain VAS, 1.3% for the dis-
ease activity VAS and 2.0% for the well-being VAS.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 153/243 Child N = 129/208
Missing values (1st–3rd quartiles) 2.0 (0.7–2.6) 1.6 (0.8–2.3)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 81.0% 82.9%
 HRQoL-PhH 47.7% 50.4%
 HRQoL-PsH 40.5% 55.0%
 Pain VAS 28.8% 27.9%
 Disease activity VAS 20.3% 25.6%
 Well-being VAS 22.2% 21.7%
Ceiling effect, median
 PF 0.0% 0.8%
 HRQoL-PhH 3.3% 3.9%
 HRQoL-PsH 2.0% 1.6%
 Pain VAS 0.6% 0.8%
 Disease activity VAS 1.3% 0.8%
 Well-being VAS 2.0% 3.1%
Items with equivalent item–scale correlation 87% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Items with item–scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.91 0.90
 PF-HW 0.89 0.91
 PF-US 0.74 0.91
 HRQoL-PhH 0.89 0.89
 HRQoL-PsH 0.81 0.81
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.00 0.29
 HRQoL-PhH 0.88 0.95
 HRQoL-PsH 0.64 0.93
Spearman’s correlation with JIA core set variables, median
 PF 0.5 0.5
 HRQoL-PhH 0.4 0.4
 HRQoL-PsH 0.2 0.3
 Pain VAS 0.3 0.3
 Disease activity VAS 0.3 0.2
 Well-being VAS 0.3 0.3
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Equal item–scale correlations (second Likert 
assumption)
Pearson’s item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 11 and 15, and for 100% 
of the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson’s item–scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 11 and 15) and 100% of items 
of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.91 for PF-LL, 0.89 for PF-HW, 0.74 
for PF-US. Cronbach’s alpha was 0.89 for HRQoL-PhH and 
0.81 for HRQoL-PsH.
Interscale correlation
The Pearson’s correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of the 
questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 6 days (6–6 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed a poor reproduc-
ibility (ICC = 0.0). The ICC for the HRQoL-PhH showed an 
almost perfect reproducibility (ICC = 0.88) while the ICC 
for the HRQoL-PsH showed a substantial reproducibility 
(ICC = 0.64).
Convergent validity
The Spearman’s correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.5 
(median = 0.5). The PF total score best correlation was 
observed with the parent’s assessment of pain (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the PhH 
with the JIA core set of outcome variables ranged from 0.3 
to 0.6 (median = 0.4), whereas for the PsH ranged from 0.1 
to 0.5 (median = 0.2). The PhH showed the best correlation 
with the parent’s assessment of pain (r = 0.7, p < 0.001) and the 
PsH with the parent global assessment of well-being (r = 0.5, 
p < 0.001). The median correlations between the pain VAS, the 
well-being VAS, and the disease activity VAS and the physi-
cian-centred and laboratory measures were 0.3 (0.2–0.5), 0.3 
(0.2–0.4), 0.3 (0.3–0.5), respectively.
Discussion
In this study, the Polish version of the JAMAR was cross-
culturally adapted from the original standard English version 
with 3 forward and 2 backward translations. According to 
the results of the validation analysis, the Polish parent and 
patient versions of the JAMAR possess satisfactory psy-
chometric properties. The disease-specific components of 
the questionnaire discriminated well between patients with 
JIA and healthy controls. The PF total score proved to dis-
criminate between the different JIA subtypes with children 
with RF− and RF + poly-arthritis having a higher degree of 
disability.
Psychometric performances were good for all domains of 
the JAMAR with few exceptions: 2 PF items (stretch arms 
and bite a sandwich or an apple) showed a lower item’s inter-
nal consistency. However, the overall internal consistency 
was excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Polish version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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